<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919565</url>
  </required_header>
  <id_info>
    <org_study_id>PL4</org_study_id>
    <nct_id>NCT03919565</nct_id>
  </id_info>
  <brief_title>Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis</brief_title>
  <acronym>HBV</acronym>
  <official_title>Study on Optimized Treatment of Peginterferon Alfa 2a or 2b in Anti-virus Treatment Naive Patients With Hepatitis b Virus Related Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more
      therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and
      anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate
      treatment of peginterferon alfa 2a/2b in anti-virus treatment naive patients with HBV related
      liver fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more
      therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and
      anti-tumor occurrence in chronic hepatitis b patients. But there still lacks of studies on
      peginterferon alfa 2a or 2b treatment in patients with HBV related liver fibrosis. We design
      this study to investigate optimized treatment of peginterferon alfa 2a/2b, comparing to
      nucleoside/nucleotide analogues, in anti-virus treatment naive patients with HBV related
      liver fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of level of liver fibrosis after anti-virus treatment</measure>
    <time_frame>48 week, 144 week</time_frame>
    <description>Liver biopsy or fibroscan would be accessed to know the change of level of liver fibrosis at 48 and 144 weeks after anti-virus treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with undetectable hepatitis b virus DNA after anti-virus treatment</measure>
    <time_frame>24 week, 48 week, 72 week, 96 week, 120 week,144 week</time_frame>
    <description>Hepatitis b virus DNA would be tested to know the ratio of patients with undetectable hepatitis b virus DNA at 6 time points after anti-virus treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with hepatitis B e antigen seroconversion after anti-virus treatment</measure>
    <time_frame>24 week, 48 week, 72 week, 96 week, 120 week,144 week</time_frame>
    <description>Hepatitis b e antigen and hepatitis b e antibody would be tested to know the ratio of patients with negative hepatitis B e antigen and positive hepatitis B e antibody at 6 time points after anti-virus treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with hepatitis b surface antigen seroconversion after anti-virus treatment</measure>
    <time_frame>24 week, 48 week, 72 week, 96 week, 120 week,144 week</time_frame>
    <description>Hepatitis b surface antigen and hepatitis b surface antibody would be tested to know the ratio of patients with negative hepatitis B surface antigen and positive hepatitis B surface antibody at 6 time points after anti-virus treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>TDF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 144 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon alfa group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.</description>
    <arm_group_label>TDF group</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alfa-2a</intervention_name>
    <description>Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.</description>
    <arm_group_label>Peginterferon alfa group</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alfa-2b</intervention_name>
    <description>Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.</description>
    <arm_group_label>Peginterferon alfa group</arm_group_label>
    <other_name>Pegintron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive hepatitis b surface antigen or hepatitis b virus DNA &gt; 0.5 year;

          2. Age from 18 to 55 years old;

          3. Fibrosis lever of F1 to F3 from liver biopsy; if liver biopsy unreachable, fibrosis
             lever of 7 to 14 kpa from fibroscan;

          4. Portal vein diameter ≤ 12 mm from liver ultrasound;

          5. Without treatment of anti-virus treatment ever before.

        Exclusion Criteria:

          1. Decompensated cirrhosis, hepatocellular carcinoma or other malignancy;

          2. Pregnancy or lactation;

          3. Other active liver diseases；

          4. Human immunodeficiency virus infection or congenital immune deficiency diseases;

          5. Severe diabetes, autoimmune diseases;

          6. Other important organ dysfunctions;

          7. Patients can not follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Peng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenxiong Xu, Doctor</last_name>
    <phone>+8613760783281</phone>
    <email>xwx1983@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Peng, Doctor</last_name>
    <phone>+8613533978874</phone>
    <email>pzp33@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Peng, Doctor</last_name>
      <phone>+8613533978874</phone>
      <email>pzp33@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liang Peng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatitis b virus</keyword>
  <keyword>peginterferon alfa</keyword>
  <keyword>liver fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

